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A B S T R A C TObjectives: Uncertainty exists regarding appropriate and affordable
use of adjuvant chemotherapy in stage II colon cancer (T3, proficient
DNAmismatch repair). This study aimed to estimate the effectiveness
and costs from a US societal perspective of a multigene recurrence
score (RS) assay for patients recently diagnosed with stage II colon
cancer (T3, proficient DNA mismatch repair) eligible for adjuvant
chemotherapy. Methods: RS was compared with guideline-re-
commended clinicopathological factors (tumor stage, lymph nodes
examined, tumor grade, and lymphovascular invasion) by using a
state-transition (Markov) lifetime model. Data were obtained from
published literature, a randomized controlled trial (QUick And Simple
And Reliable) of adjuvant chemotherapy, and rates of chemotherapy
use from the National Cooperative Cancer Network Colon/Rectum
Cancer Outcomes study. Life-years, quality-adjusted life expectancy,
and lifetime costs were examined. Results: The RS is projected to
reduce adjuvant chemotherapy use by 17% compared with current
treatment patterns and to increase quality-adjusted life expectancy
by an average of 0.035 years. Direct medical costs are expected tont matter Copyright & 2012, International Society
r Inc.
.1016/j.jval.2012.07.012
nford.edu.
ondence to: John Hornberger, 3715 Haven Avenue, Sdecrease by an average of $2971 per patient. The assay was cost saving
for all subgroups of patients stratified by clinicopathologic factors.
The most influential variables affecting treatment decisions were
projected years of life remaining, recurrence score, and patients’
disutilities associated with adjuvant chemotherapy. Conclusions: Use
of the multigene RS to assess recurrence risk after surgery in stage II
colon cancer (T3, proficient DNA mismatch repair) may reduce the use
of adjuvant chemotherapy without decreasing quality-adjusted life
expectancy and be cost saving from a societal perspective. These
findings need to be validated in additional cohorts, including studies
of clinical practice as assay use diffuses into nonacademic settings.
Keywords: cancer, cost-effectiveness, cost-utility, health economics,
technological change.
Copyright & 2012, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Colorectal cancer is the third most common cancer in the United
States, and the second leading cause of cancer mortality, result-
ing in 49,920 deaths in 2009 [1]. Based on estimates from the
National Cancer Institute’s Surveillance, Epidemiology, and End
Results (SEER) program, an estimated 105,000 persons were
diagnosed with colon cancer in 2010 [2]. At least one-quarter of
new cases are stage II cancer (American Joint Committee on
Cancer [AJCC] staging T3-T4 N0M0, Dukes’ B2, tumor has grown
into or through the outermost layers of the colon and may be
attached or grown into other nearby tissues or organs [T3-T4], no
regional lymph node [LN] metastasis [N0], no distant metastasis
[M0]) [3,4].
Surgical resection is the cornerstone of management for
patients with stage II colon cancer [3,5]. Because approximately
only one-quarter are expected to experience a recurrence within
5 years of diagnosis, the National Comprehensive CancerNetwork (NCCN) and the American Society of Clinical Oncology
guidelines state that the routine use of adjuvant chemotherapy
(aCTX) for all medically fit patients is not recommended [3,5].
Guidelines recommend physicians to discuss with patients
potential cure rates with surgery alone and the associated
toxicities with aCTX [3].
Several clinicopathological characteristics have been identi-
fied as risk factors for disease recurrence and are commonly used
to select patients for treatment. These include T4 tumor, bowel
perforation, bowel obstruction, poorly differentiated tumor, lym-
phovascular invasion (LVI), and number of LNs examined [3,5].
The presence of deficient DNA mismatch repair (MMR) (or
microsatellite instability high) is a favorable risk factor and may
indicate reduced benefit from aCTX with fluoropyrimidine-only
regimens [6].
In unselected patients, the potential benefit of aCTX in
patients with stage II colon cancer (T3, proficient DNA MMR) is
small. The QUick And Simple And Reliable (QUASAR) study was afor Pharmacoeconomics and Outcomes Research (ISPOR).
uite 100, Menlo Park, CA 94025.
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pared with observation alone in patients with complete resection
for colon or rectal cancer, no evidence of distant metastases, and
uncertain benefit from adjuvant therapy based on physician
assessment [7]. Chemotherapy resulted in an approximate 4%
survival benefit at 3 years among all 3239 patients enrolled in the
trial; the relative risk for recurrence with chemotherapy versus
observation was 0.78 (95% confidence interval [CI] 0.64–0.95) [7].
The relative risk of recurrence for the 2146 patients with stage II
colon cancer was 0.82 (95% CI 0.65–1.08). The Multicenter Inter-
national Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the
Adjuvant Treatment of Colon Cancer study evaluated 2246
patients with stage II or stage III colon cancer after surgery for
curative intent randomized to 5FU/LV plus oxaliplatin (FOLFOX)
or 5FU/LV alone [8]. A subset analysis of the 899 patients with
stage II cancer showed no difference in overall survival (hazard
ratio ¼ 1.00; 95% CI 0.70–1.41) and in disease-free survival (hazard
ratio ¼ 0.91; 95% CI 0.61–1.36). In an unplanned subgroup analy-
sis, patients with high-risk features had a trend for improved
disease-free survival (hazard ratio ¼ 0.74; 95% CI 0.56–1.06) [9]. By
inference, patients without high-risk features should have a
trend toward worse disease-free survival with FOLFOX compared
with 5FU/LV alone. The NCCN guideline states that FOLFOX is not
considered as an appropriate therapy for patients without high-
risk features [5]. The large variability in the use of aCTX,
especially oxaliplatin-containing regimens, reported in the NCCN
Colon/Rectum Cancer Outcomes study suggests that identifying
patients at the greatest risk who might benefit from adjuvant
treatment is a challenge [10].
Substantial interest exists in using gene-expression profiles to
estimate prognosis and predict response to aCTX in stage II colon
cancer [11]. A 12-gene reverse transcriptase-polymerase chain
recurrence score (RS) assay (Genomic Health, Inc., Redwood City,
CA) that quantifies the risk of recurrence in stage II colon cancer
(0-lowest, 100-highest) was validated by prospective analysis of
archived paraffin-fixed tumor tissue from 1436 patients with
stage II cancer who participated in the QUASAR study [12]. The
RS was found to be a statistically significant, independent pre-
dictor of recurrence risk (P ¼ 0.004), disease-free survival
(P ¼ 0.01), and overall survival (P ¼ 0.04) [12]. Other independent
research groups have confirmed that the RS is an independent
predictor of recurrence risk [13,14]. The specific aim of this study
was to assess long-term patient outcomes and costs of the RS
when used to guide the use of aCTX in ‘‘average-risk’’ (T3,
proficient DNA MMR) stage II colon cancer compared with the
prevailing use of traditional clinicopathological criteria.Methods
Analytical Overview
The target population was defined as patients with stage II colon
cancer who have undergone surgery in whom life expectancy
and comorbidities do not preclude the consideration of aCTX.
Patients with T4 tumor or the presence of deficient DNA MMR
were excluded. We compared the RS for deciding the use of aCTX
against current practice, which includes guideline-recommended
clinicopathological characteristics that predict the risk of recur-
rence, for example, number of LNs examined (o12 or 412), LVI
(yes/no), and tumor grade (high/low).
A state-transition (Markov) analysis was conducted to esti-
mate a representative patient’s life expectancy and quality-
adjusted life-years (QALYs) with and without the RS (Fig. 1A).
QALY was calculated by multiplying the time in specific health
states (without recurrence and after recurrence) by correspond-
ing health-related quality-of-life weights or utilities [15]. Utilityweights for no recurrence, recurrence, and chemotherapy were
derived from the relevant literature [16].
We obtained numbers of patients diagnosed with stage II
colon cancer from SEER (National Cancer Institute) database, and
computed percentages of patients by age. Median age was 69.5
(interquartile range 61.5–75.5) years.
The propensity of a patient to receive aCTX based on clin-
icopathological factors was derived from analyses published by
Earle et al. [10] using the NCCN Colon/Rectum Cancer Outcomes
Database. These multivariate analyses showed that the four most
influential and statistically significant variables associated with
propensity to prescribe aCTX were age, number of LNs examined,
LVI, and tumor stage. The proportions of chemotherapy patients
receiving different types of chemotherapy were extracted from
this study and from surveys of medical oncologists [10,17].
By using estimates from the multivariate regression model
published by Earle et al., we generated the propensity to receive
chemotherapy as a function of years of life remaining, number of
LNs examined, and LVI. Results are presented for patients with T3
lesions only, as T4 tumors are considered ‘‘high risk’’ and the use
of adjuvant treatment is routine. We applied a polynomial
approximation to the age covariate, which was analyzed as a
bracketed variable in their regression, to obtain propensity to
receive chemotherapy as a function of expected years of life
remaining. The presence of LVI, fewer LNs examined, and
younger age increased the propensity to receive chemotherapy.
By using the life-table methods described above, we computed
the benefit with chemotherapy in life-years gained and QALYs
gained as a function of years of life remaining a patient may
expect if she or he does not have tumor recurrence. Recurrence
rates are based on average for patients with T3 tumors. Relative
risk reduction of chemotherapy is set to 0.18 as described in the
main text. The benefit of chemotherapy increases for patients
with longer expected years of life remaining (Fig. 2).
For the RS, a patient was assumed to receive aCTX if aCTX was
expected to increase quality-adjusted life expectancy. The model
estimates the difference between the QALY gained with aCTX for
preventing recurrence (Q2; Fig. 1B) and the utility loss of aCTX’s
inconvenience and toxicities (Q3). A patient was assumed to receive
aCTX if the difference was positive (Q2–Q34 0). The QALY gained
corresponds with the risk of recurrence (derived from the RS) and
the predicted years of life remaining for the patient if he or she had
not been diagnosed with colon cancer. Therefore, the decision to
receive aCTX is not based only on the RS, but also permits the
consideration of other factors, such as years of life remaining and
inconvenience/toxicities of aCTX. Given the same RS, more years of
life remaining is associated with a higher Q2; hence, the propensity
to recommend aCTX is higher. This assumption is consistent with
current practice patterns reported by Earle et al. [10], where the
propensity to prescribe aCTX is highest among younger patients.Risk of Recurrence and Death
The 3-year risk of recurrence, based on results reported from the
QUASAR validation study, varied between 10% and 26% for
patients with T3 lesions [12]. The relative reduction in recurrence
risk associated with aCTX, compared with observation alone, was
set to 0.18, based on analyses reported for stage II colon cancer
(T3, proficient DNA MMR) from the QUASAR study [7]. When
applied to the 3-year recurrence risk with observation alone in
patients with T3 stage II colon cancer with intact MMR, aCTX is
estimated to reduce the recurrence risk at 3 years (i.e., absolute
risk reduction) by an average of 3.2% (range 1.9%–5.2%).
The risk of mortality related to relapse of colon cancer was
obtained from the SEER (National Cancer Institute) database [2].
Risk of death from causes not related to colon cancer was derived
Fig. 1 – (A) Clinical decision model. aCTX, adjuvant chemotherapy; NCCN, National Comprehensive Cancer Network;
QUASAR, QUick And Simple And Reliable; square, decision node; circle, random variable of predicted aCTX utilization rates;
double circle in box, Markov node of per-cycle risk of subsequent events. Propensity to treat is stratified by age, absolute
benefit in life expectancy, and stage. Current risk assessment—model based on risk factors derived from QUASAR results as
summarized in NCCN guidelines (lymph nodes examined, lymphovascular invasion, histologic grade, perforation, tumor
stage). Estimates of predicted rate of aCTX use are based on multivariate regression model of NCCN Colon/Rectum Cancer
Outcomes database. yAdd multigene reverse transcriptase polymerase chain reaction assay—model based on updated
results from QUASAR that included recurrence score assay results. Estimates of predicted rate of aCTX use are based on
anticipated years of life gained with aCTX. (B) Electing adjuvant chemotherapy. Q1, QALY with stage II colon cancer
postsurgery without chemotherapy; Q2, QALY gain associated with preventing recurrence; Q3, QALY loss associated with
chemotherapy. Model will indicate aCTX recommendation if Q24 Q3. QALY, quality-adjusted life-year.
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Control and Prevention.
Costs and Quality-of-Life Adjustments
Regimens, dosages, and number of cycles were cited from NCCN
colon cancer guidelines [5]. Cost of aCTX was derived for eachdrug from Medicare Part B average sales price available from the
Center for Medicare & Medicaid Services, effective April 1, 2011.
The oxaliplatin patent expired on July 1, 2009; however, the
generic pricing was unavailable at the time of writing. All costs
were standardized to 2011 US dollars [18]. Cost of chemotherapy
administration per cycle was cited from Aballea et al. [19], which
included costs for administration, infusion pump, and
Fig. 2 – Optimal aCTX recommendation (red, yellow, green colors) and net QALYs between receiving aCTX and no aCTX
(numbers inside cells) as a function of YLR (x-axis; 10–40 years), RS (y-axis; 1–70), and patient expression of loss in quality of
life associated with aCTX (o0.31, 0.31–0.63, 40.63). 1) Red area represents combination of RS and YLR where net QALYs of
receiving aCTX is o0 for patients who express limited loss in quality of life associated with aCTX (i.e., loss of utility with
aCTX ¼ 0.63). 2) Green area represents combination of RS and YLR where net QALY of receiving a aCTX is 40 for patients
who express substantial loss in quality of life associated with aCTX (i.e., loss of utility with aCTX o0.31). 3) Yellow area
represents the combination of RS and LYR for net QALY for patients who express intermediate loss in quality of life
associated with aCTX (i.e., loss of utility with aCTX between 0.31 and 0.63). aCTX, adjuvant chemotherapy; QALY, quality-
adjusted life-year; RS, recurrence score; YLR, years of life remaining.
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percentage of FOLFOX, 5FU/LV, and capecitabine prescribed for
stage II colon cancer, in actual US practice was obtained from Earle
et al. [10]. Costs for common supportive care and aCTX-associated
adverse events were derived from published literature [20–24], as
were incidences of common aCTX-associated adverse events
[25–28]. Costs from time of recurrence until death were estimated
in net present value on the basis of analysis of SEER-Medicare data
[23]. The list price of the RS utilized was $3200 (Table 1).
Quality-of-life adjustments (utilities) were assigned to three
health states in the model: no recurrence, recurrence, and lossdue to chemotherapy [19, 29–31]. We searched the literature
published from 1966 to May 2012 by using PubMed using search
terms such as o colon cancer4 o utilities4 o disutility4
o preferences4 and o quality of life4. We also searched for
publications on cost-utility analyses of interventions in colon or
colorectal cancer. Last, we examined the CEA Registry maintained
by the Institute of Clinical Policy Research & Health Policy Studies at
Tufts Medical Center [32]. The registry is a comprehensive database
of more than 2000 cost-utility analyses on a wide variety of diseases
and treatments. We restricted the criteria for eligibility to published
articles, excluding case reports and abstracts.
Fig. 3 – Change in use of aCTX based on years of life
remaining (all patients regardless of lymphovascular
invasion or number of lymph nodes sampled). The solid
lines show the average propensity to treat. The dotted lines
reflect the 95% confidence interval derived from Earle et al.
[10]. aCTX, adjuvant chemotherapy.
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ing aCTX was 50%—that is, the point of indifference—
when patients’ expected years of life remaining is approximately
21 years. Applying the risk reduction with aCTX, the estimated
QALY gain with aCTX is 0.47 years for patients at the indifference
point. It was assumed that this reflects the average utility loss
associated with prescribing aCTX for stage II cancer (T3, profi-
cient DNA MMR). Other studies have elicited patients’ reports on
utility loss of aCTX, with ranges varying from 0.25 to 0.65.
Sensitivity analyses were utilized to explore implications of the
wide range of utilities. A base-case utility of 0.79 was assigned for
the time between diagnosis and no recurrence, recurrence, or
death; a utility of 0.6 was assigned for time from recurrence until
death [16,31,33]. Details on the identified literature are available
in Supplemental Materials at Question 3, Supplemental Table 2,
found at http://dx.doi.org/10.1016/j.jval.2012.07.012.Other Policy Assumptions and Analyses
The model adopts a US societal perspective and forecasts outcomes
and costs over a representative patient’s lifetime according to
economic evaluation guidelines [34]. A fixed annual discount rate
of 3% was applied [35]. Extensive one-way sensitivity analyses were
performed, in which parameters were varied individually through
their ranges to assess their influence on outcomes and costs.
Ranges for parameters were based on 95% CIs when applicable.
Probabilistic sensitivity analyses were conducted on the model
parameters by using a second-order Monte Carlo simulation (com-
putational algorithm based on repeated random sampling). The
distribution of each parameter was assigned standard distributions
reported for the specific parameter types [36].
The percentage of variation, or ‘‘influence,’’ on QALYs
explained by years of life remaining, utility loss of aCTX, and
the RS was computed by using boosted regression tree analysis
[37,38]. The algorithm was run by using the Boosted Algorithm
plug-in for STATA (Version 9.2) on the 63,000 different possible
combinations of years of life remaining (from 10 to 40 years, by1-year increments), utility loss of aCT (0.30–0.6, by 0.01-unit incre-
ments), and RS (1–70, by 1-unit increments). The estimated influ-
ences of the three variables were standardized to add up to 100%.
Role of the Funding Source
The study was funded by Genomic Health through an indepen-
dent research contract. The funding source had no role in the
design of the study, collection, analysis, or interpretation of the
data; or approval of the manuscript.Results
The recommended use of aCTX based on the RS depends on
years of life remaining and the disutility attached to aCTX’s
inconvenience and toxicities (Q3) (Fig. 2). The red area illustrates
where the overall QALY change associated with aCTX versus
observation alone is expected to be negative. Green area illus-
trates where the overall QALY change associated with aCTX is
expected to be positive. The yellow area represents where the
QALY change may be positive or negative depending on how a
patient assesses the disutility of aCTX’s inconvenience and
toxicities.
The propensity to prescribe aCTX using the RS, compared
with prevailing prescribing treatment patterns as reported by
Earle et al. [10], is contrasted in Figure 3. For a representative
patient with relatively less years of life remaining, adoption of
the RS would decrease the use of aCTX. For a representative
patient with relatively more years of life remaining, use of the RS
would increase aCTX prescribing. The average age of patients
with stage II colon cancer is more than 65 years, such that the net
effect of using the RS as described here would be to reduce the
use of aCTX by an average of 17% (Table 2).
The use of RS is expected to reduce aCTX prescribing regard-
less of the number of LNs sampled, presence of LVI, or high-
grade histology (Table 2). The average gain in QALYs is 0.035
years (range 0.027–0.104 years). Most of the gain in QALYs results
from avoiding aCTX when the inconvenience and toxicities out-
weigh the benefits of reduced recurrence. Because RS use is
expected to lower the total costs of aCTX, lifetime costs are
projected to decline on average by $2971. The use of the assay
dominates all scenarios (i.e., improves outcomes and lowers
costs).
Sensitivity Analyses
The RS assay is predicted to improve QALYs throughout the range
of all variables (see Supplemental Materials Question 6,
Supplemental Table 6, found at http://dx.doi.org/10.1016/j.jval.
2012.07.012). For all but three of these sensitivity analyses, the
assay is cost saving. The assay increased cost when 1) utility loss
associated with chemotherapy is low (utility during chemother
apy 40.69); 2) the quality of life associated with no recurrence
postsurgery is higher (utilities after surgery, no recurrence ¼1); or
3) the discount rate is 0%. The probabilistic sensitivity analyses
show that the adoption of RS was cost saving in more than 80% of
the scenarios. The boosted regression analyses found that years
of life remaining had the most influence on QALYs (54%) followed
by the RS (26% influence) and utility loss of aCTX (20% influence).Discussion
There is a significant need for improved risk stratification in
patients with stage II colon cancer [39–41]. Several recent efforts
have described gene expression profiles associated with the risk
of recurrence [12,42]. One such tool, the RS, has recently been
Table 1 – Probabilities, resource use, utility weights, and
unit costs applied in the analyses.
Variable Base-
case
value
Reference
Incidence of adverse events with
aCTX (%)
Neutropenia 28.6 [25–28]
Febrile neutropenia 1.2 [25–28]
Diarrhea 9.8 [25–28]
Death 0.1 [25–28]
Neuropathy 61.7 [25–28]
% of patients using aCTX regimens
FOLFOX 67 [10]
5FU/LV 17 [17]
Capecitabine 13 [17]
Others 3 [17]
Quality-of-life weights (utilities)
Remission 0.85 [19,30,33]
Relapse 0.60 [19,29]
Loss due to aCTX 0.47 [19,31]
Chemotherapy cost ($)
FOLFOX 37,330 [18]
5FU/LV 3,086 [18]
Capecitabine 16,136 [18]
Adverse events cost ($)
Neutropenia 4,400 [20]
Febrile neutropenia 12,500 [21]
Diarrhea 284 [20]
Neuropathy 5,000 Expert
opinion
Supportive care ($) 12,850 [22]
From time of recurrence to death ($) 200,000 [23]
Recurrence score assay ($) 3,200 Manufacture
list price
Other inputs (%)
Annual mortality with metastatic
colon cancer
40 [2]
Relation risk reduction of aCTX 18 [7]
Discount rate-annual 3 [35]
Note. All costs adjusted to 2010 USD.
aCTX, adjuvant chemotherapy; FOLFOX, leucovorin calcium, fluor-
ouracil, and oxaliplatin; FU, fluorouracil; LV, leucovorin; USD, US
dollar.
* Incidence of adverse events weighted by distribution of aCTX
regimen.
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of archival tissue of the QUASAR trial. The current analysis
demonstrates that the use of a prognostic assay such as the RS
can potentially reduce the use of aCTX, improve quality-adjusted
survival, and save cost among patients with stage II colon cancer
(T3, proficient DNA MMR).
The effect of the RS on long-term clinical outcomes and costs,
when combined with factors such as years of life remaining and
patient perception of disutility associated with aCTX, was mod-
eled. Among patients with relatively less years of life remaining,
the RS is predicted to reduce aCTX more than if decisions
were based on currently recommended criteria. Conversely, for
patients with relatively more years of life remaining, using the RS
would increase the likelihood of receiving aCTX. Following this
approach in the overall population, the average likelihood of
aCTX prescribing would decline and population-averagedquality-adjusted life expectancy would increase, regardless of
the status of traditional clinicopathological factors. Because the
average costs of aCTX as prescribed in 2010 exceed $20,000 under
all scenarios, use of the RS would result in net cost savings within
the US health care system, assuming an RS assay unit cost
between $3000 and $3400, according to our sensitivity analyses.
With approximately 20,000 patients with T3, MMR proficient
stage II colon cancer diagnosed per year, the annual savings of
adopting the 12-gene RS within the United States are estimated
to be $59 million.
Interpretation of these findings should consider potential
limitations. First, propensity to prescribe aCTX is likely to vary
by institution, and NCCN institutions may not be fully represen-
tative of community practice. However, the NCCN institutions are
widely dispersed geographically, and the frequency of the use of
adjuvant treatment is similar to that reported in SEER-Medicare
data [4]. Second, the costs of chemotherapy, administration, and
appropriate supportive care are likely to depend on location and
coverage policies. However, sensitivity analyses over wide ranges
in the model did not reveal these to be influential variables in the
analyses. Third, estimates of the risk of recurrence were based on
results reported from the QUASAR validation study; patients’
characteristics, life-years remaining, and RS distribution may
differ from other colon cancer populations receiving alternative
systemic therapies. Fourth, validation of the RS would be desir-
able in patients with clinically high-risk features, for whom
oxaliplatin-based regimens may be appropriate. This study was
restricted to patients without T4 lesions; as such, a minority of
patients in this population are expected to have high-risk
features that would warrant consideration of oxaliplatin. More-
over, the cost-effective result was robust under scenarios with
greater clinical effectiveness of aCTx. Last, these findings appear
to be most sensitive to the assumption about the average utility
loss associated with inconvenience/toxicities of aCTX. Given that
approximately twice as many patients in the United States are
prescribed aCTX than are at risk, the assay was found to be more,
or less, cost-effective if the inconvenience and toxicities of aCTX
were perceived as more, or less, detrimental to quality of life.
This finding highlights the importance of the patient perspective
in this critical decision, and improved methods to predict side
effects for individual patients.
More than a decade has passed since the first randomized
trial evidence showed the benefit of aCTX in patients with stage II
colon cancer [25]. Subsequent analyses of the same trial helped
identify clinicopathological factors that predict high risk of
recurrence [5]. Analyses of more than 43,000 Medicare-eligible
patients showed no survival advantage of aCTX for older patients
with stage II colon cancer regardless of the presence or absence
of high-risk factors [43]. This recent study provides supportive
evidence for our observation that older patients (i.e., fewer
expected years of remaining life) are less likely to benefit from
adjuvant therapy in terms of quality-adjusted survival [44]. The
analyses herein shows that the projected years of life remaining,
such as the patients who are elderly or relatedly those who have
multiple comorbidities that predict shorter survival, is important
but insufficient as a criterion for recommending appropriate
and affordable use of aCTX. Instead, these analyses show how
projected years of life remaining may be combined optimally
with genomic information and a measure of the expected
disutility associated with chemotherapy.
With the introduction of the RS into practice, several areas
requiring further analysis are apparent. For example, it is com-
monly assumed that all patients with T4 colon cancers have a
risk high enough to warrant adjuvant therapy. Additional study is
needed to determine whether the RS assay could identify
patients within this group who might be spared adjuvant treat-
ment. Second, the current model was based on a patient
Table 2 – Model results based on patient characteristics.
Lymph nodes sampled Lymphovascular invasion and high grade
Both not present (74%)* Both present (26%) All (100%)
o12 (13%)*
Change in use of aCTX (%) 35 56 40
QALY gained 0.063 0.104 0.073
Net cost ($) 9,133 16,402 11,102
ICER Dominant Dominant Dominant
Z12 (87%)
Change in use of aCTX (%) 11 27 14
QALY gained 0.027 0.049 0.031
Net cost ($) 851 6,245 1,710
ICER Dominant Dominant Dominant
All
Change in use of aCTX (%) 14% 31% 17%
QALY gained 0.030 0.056 0.035
Net cost ($) 1,695 7,871 2,971
ICER Dominant Dominant Dominant
aCTX, adjuvant chemotherapy; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
* Percentages in parentheses represent the distribution of lymph nodes sampled and lymphovascular invasion reported by Earle et al. [10].
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effectiveness of the RS assay could potentially increase if the
benefit of adjuvant treatment with oxaliplatin is higher than with
5-FU/LV alone in patients at the highest risk. This analysis was
not intended to address issues of analytical validity or clinical
validity, which will ideally be addressed by follow-up studies. Our
analysis represents an example of comparative effectiveness
research for novel technologies, in which data from prospective
studies are still emerging. As additional data from such
studies become available, they can be readily integrated into
our model. We propose that our model might guide a future
prospective evaluation of the RS. Last, real-life economic implica-
tions of the assay are highly dependent on the assay’s impact
on actual treatment decisions. As such, follow-up economic
analysis of future clinical utility studies of this and other multi-
gene colon cancer assays is merited to confirm the findings of
this study.
The management of stage II colon cancer represents a
challenging context for patient-physician communication and
treatment decision making. The current analysis indicates that
the RS assay is a cost-effective decision tool that can be used to
assist in making decisions regarding adjuvant therapy in stage II
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